Innovation Pharmaceuticals Stock Probability of Future Pink Sheet Price Finishing Over 50.01
| IPIX Stock | USD 0.0003 0.0001 25.00% |
Innovation |
Innovation Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Innovation Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Innovation Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Innovation Pharmaceuticals is way too risky over 90 days horizon | |
| Innovation Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Innovation Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Innovation Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Innovation Pharmaceuticals currently holds 1.24 M in liabilities with Debt to Equity (D/E) ratio of 0.36, which is about average as compared to similar companies. Innovation Pharmaceuticals has a current ratio of 0.59, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Innovation Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Innovation Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innovation Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innovation to invest in growth at high rates of return. When we think about Innovation Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 18 K. Net Loss for the year was (7.04 M) with profit before overhead, payroll, taxes, and interest of 18 K. | |
| Innovation Pharmaceuticals currently holds about 2.97 M in cash with (6.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Innovation Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Innovation Pink Sheet often depends not only on the future outlook of the current and potential Innovation Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Innovation Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 472.2 M | |
| Short Long Term Debt | 250 K | |
| Shares Float | 439.3 M |
Innovation Pharmaceuticals Technical Analysis
Innovation Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Innovation Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Innovation Pharmaceuticals. In general, you should focus on analyzing Innovation Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Innovation Pharmaceuticals Predictive Forecast Models
Innovation Pharmaceuticals' time-series forecasting models is one of many Innovation Pharmaceuticals' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Innovation Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Innovation Pharmaceuticals
Checking the ongoing alerts about Innovation Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Innovation Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Innovation Pharmaceuticals is way too risky over 90 days horizon | |
| Innovation Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Innovation Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Innovation Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Innovation Pharmaceuticals currently holds 1.24 M in liabilities with Debt to Equity (D/E) ratio of 0.36, which is about average as compared to similar companies. Innovation Pharmaceuticals has a current ratio of 0.59, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Innovation Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Innovation Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innovation Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innovation to invest in growth at high rates of return. When we think about Innovation Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 18 K. Net Loss for the year was (7.04 M) with profit before overhead, payroll, taxes, and interest of 18 K. | |
| Innovation Pharmaceuticals currently holds about 2.97 M in cash with (6.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Additional Tools for Innovation Pink Sheet Analysis
When running Innovation Pharmaceuticals' price analysis, check to measure Innovation Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovation Pharmaceuticals is operating at the current time. Most of Innovation Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Innovation Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovation Pharmaceuticals' price. Additionally, you may evaluate how the addition of Innovation Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.